Five SAEs occurred, four of which were unrelated to TIL/IL-2/anti-PD-1 therapy: myocardial infarction (MI) (only SAE considered treatment-related) - possibly linked to nivolumab (anti-PD-1) due to pre-existing cardiovascular risks. This evidence concerns the gene PDCD1 and myocardial infarction.